Regeneron Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹65.2K Cr
- DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies. - Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. - Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.
From Regeneron Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹621.52
Market Cap
₹65.2K Cr
P/E Ratio
15.5
Revenue Rank
Margin Rank
How does Regeneron Pharmaceuticals, Inc. rank in Biotechnology?
Compare Regeneron Pharmaceuticals, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies.
- →Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. net sales; anticipated sequential unit demand growth consistent with Q1.
- →EYLEA sales declining due to conversion to EYLEA HD, competition, and affordability; expected mid- to high-teens decline in Q2.
- →Libtayo sales growing 54% globally, with continued uptake in skin cancers and lung cancer; early growth from new adjuvant CSCC indication.
- →Pipeline advancements (e.g., cemdisiran, olatorepatide, garetosmab) anticipated to support long-term revenue expansion.
- →Broad market opportunities in complement-mediated diseases, metabolic diseases, oncology, and rare diseases.
- →Focus on lifecycle management, label expansions, and next-generation therapies to sustain growth momentum.
📈 Profitability & Margins
Rank 4- →Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.
- →The company anticipates sustained growth in key products like DUPIXENT (31% YoY growth) and Libtayo (54% YoY growth).
- →Sanofi collaboration revenue is expected to increase starting Q3 2026 as the Sanofi development balance will be fully repaid by end of Q2.
- →GAAP gross margin guidance was updated to 77%-78% for 2026 due to temporary manufacturing interruptions, with margins expected to improve by end of Q2.
- →Ongoing investments in R&D and multiple late-stage pipeline programs suggest continued prospects for revenue and profit expansion.
- →Share repurchase programs totaling $3 billion authorized, indicating confidence in financial outlook and earnings growth.
- →Overall, the company feels well-positioned for long-term value creation driven by pipeline progress and commercial execution.
🏗️ Capital Expenditure Plans
Yes- →Regeneron continues aggressive investment in R&D, supporting late-stage and early-stage pipeline programs across multiple therapeutic areas including hematology/oncology, complement-mediated diseases, and immunology.
- →The company has authorized a new $3 billion share repurchase program, reflecting confidence in its financial position and business outlook.
- →Strategic collaborations include:
- → - Partnership with Telix for co-development and commercialization of next-generation radiopharmaceutical therapies.
- → - Collaboration with TriNetX to leverage real-world clinical data linked to genomic and proteomic information, accelerating drug discovery.
- →Capital allocation balances internal investment in science and pipeline with capital returns to shareholders and business development.
- →Manufacturing investments are ongoing, including resumption and scaling of production at the Limerick, Ireland site after a temporary interruption.
- →The company is also committed to patient access initiatives, including matching up to $200 million in 2026 to support affordability.
💰 Fundraising & Capital Structure
No information- →There is no mention of any new fundraising through debt or equity in the provided document.
- →The company ended Q1 2026 with $15.8 billion in cash and marketable securities less debt, indicating a strong cash position.
- →The Board of Directors authorized a new $3 billion share repurchase program, reflecting confidence in the business and financial position.
- →There is no discussion in the transcript about plans to raise capital via issuing new debt or equity.
- →Capital allocation focuses on balancing internal investment, share repurchases, dividends, and business development rather than raising new funds.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were Regeneron Pharmaceuticals, Inc. Q2 FY26 results?
- DUPIXENT sales expected to exceed $30 billion globally, driven by growth across all indications and geographies. - Continued strong uptake of EYLEA HD with 52% year-over-year growth in U.S. - Regeneron delivered double-digit growth in Q1 2026 with total revenues up 19% YoY and non-GAAP EPS increasing 15%.
What is Regeneron Pharmaceuticals, Inc. share price analysis?
Regeneron Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 15.5 with a market cap of $65,160. Investors should review the full earnings analysis for detailed insights.
Is Regeneron Pharmaceuticals, Inc. planning capital expenditure?
- Regeneron continues aggressive investment in R&D, supporting late-stage and early-stage pipeline programs across multiple therapeutic areas including hematology/oncology, complement-mediated diseases, and immunology.
Keep Regeneron Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.